For patients with advanced triple-negative breast cancer who are candidates for treatment with the checkpoint inhibitor pembrolizumab due to a positive PD-L1 status, adding the antibody-drug conjugate sacituzumab govitecan may improve outcomes compared to a combination of pembrolizumab with chemotherapy.
These are the initial findings from the Phase 3 ASCENT-04/KEYNOTE-D19 study, initially presented at the American Society of Clinical Oncology annual meeting last year and now published in the Recent England Journal of Medicine (2026; DOI: 10.1056/NEJMoa2508959). This research offers a potentially significant advancement in the treatment of an aggressive form of breast cancer, where new options are critically needed.
Sign up to read more
Dear readers,
this article is only visible for logged-in users.
Please log in or register.
With a free registration you benefit from the following advantages:
Get access to non-public content
